Search results
Duopharma Biotech Berhad Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
Simply Wall St. via Yahoo Finance· 1 day agoThe company's shares are up 1.7% from a week ago. Risk Analysis It...
Newron's schizophrenia add-on improves symptoms, charging up case for phase 3 test
FierceBiotech· 2 days agoNewron Pharmaceuticals’ add-on schizophrenia treatment improved both positive and negative symptoms...
Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech
Investor's Business Daily· 13 hours agoNeurocrine developed the drug with Takeda Pharmaceutical. Abrahams raised his price target on...
3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
InvestorPlace· 2 days agoBiotech stocks offer the opportunity to invest in life-saving treatments and drugs. If you want to...
Citi names 3 biotech stocks to play a growing $2.9 billion opportunity — giving one about 50% upside
CNBC· 1 day agoThe outlook is starting to look bright for biotech stocks, according to some. With markets now...
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
InvestorPlace· 7 days agoIf you have a high tolerance for volatility then the biotech sector might be for you. Biotech stocks...
Stock Market Crash Warning: Don't Get Caught Holding These 3 Biotech Stocks
InvestorPlace· 2 days agoInvesting in the biotech sphere isn’t for the faint of heart, and you should steer clear of the ...
Can biotech startups upstage Eli Lilly and Novo Nordisk?
The Economist· 1 day agoAn index of American big pharma rose by a third, outperforming the broader stockmarket thanks to...
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Zacks via Yahoo Finance· 2 days agoThe sector mainly comprises pharma/biotech and medical device companies. With many pharma and ...
Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
KTLA-TV Los Angeles· 20 hours agoMoleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting ...